Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

37.32
-0.0800-0.21%
Post-market: 37.27-0.0500-0.13%18:17 EDT
Volume:10.24M
Turnover:382.69M
Market Cap:166.63B
PE:9.32
High:37.65
Open:37.64
Low:37.17
Close:37.40
52wk High:64.16
52wk Low:35.12
Shares:4.47B
Float Shares:3.19B
Volume Ratio:0.79
T/O Rate:0.32%
Dividend:1.79
Dividend Rate:4.78%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:5.12
PE(LYR):10.31

Loading ...

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

TIPRANKS
·
Sep 17

Novo Nordisk announces FRONTIER5 Phase 3b results for denecimig

TIPRANKS
·
Sep 17

Novo, Orbis Sign up to $1.4 Billion Deal to Develop Oral Drugs

Reuters
·
Sep 17

After Ozempic, Novo Nordisk Bets On Anthropic—While Pharma Still Awaits AI's First Approved Drug

Bellwether Stocks Movement
·
Sep 17

Sector Update: Healthcare

MT Newswires Live
·
Sep 17

Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal is Betting on It.

Dow Jones
·
Sep 17

Novo Nordisk Will Use Anthropic's Claude for Drug Research

Dow Jones
·
Sep 17

Novo Nordisk A/S Series B Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Sep 17

Novo (NVO) Partners with Anthropic on AI Drug Discoveries

TIPRANKS
·
Sep 16

Novo Nordisk announces collaboration with Anthropic

TIPRANKS
·
Sep 16

LIVE Markets-from Ozempic Face to K-Beauty Factories: the Next Beauty Bet

Reuters
·
Sep 15

Novo CEO Urges Staff to Embrace More Customer-Focused Culture

Reuters
·
Sep 15

Sector Update: Healthcare

MT Newswires Live
·
Sep 15

Novo Nordisk Stock (NVO) Is Falling Despite Rebrand to ‘Novo’ — Here’s Why

TIPRANKS
·
Sep 15

Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market

Bellwether Stocks Movement
·
Sep 15

Novo Nordisk rebranding as ‘Novo,’ announces cultural reset

TIPRANKS
·
Sep 15

GSK Doubles Down On Oncology: Buys Global Rights To Chimagen's Trispecific TCE For Up To $750 Million

Options & Short Sell
·
Sep 15

Lilly's Foundayo Grabs 30% Of New U.S. Orforglipron Patients, Chipping Away At Novo's Head Start

Options & Short Sell
·
Sep 15

Lilly Says Foundayo Has Captured over 30% of New US Patients on Oral Weight-Loss Drugs

Reuters
·
Sep 15

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Sep 15